Suggestions
Ginger Johnson
President @ Lumanity | PhD, Biotechnology, Early Venture Investing
Ginger S. Johnson, PhD, is the President of Commercial BioConsulting at Lumanity, a role in which she leads core assessment and strategic consulting engagements with a special focus on Central Nervous System (CNS) related categories.14
Professional Background
Dr. Johnson has an extensive and diverse background in the life sciences industry:
- Current Role: President of Commercial BioConsulting and Co-Lead for Central Nervous System at Lumanity2
- Previous Positions:
- Director of Life Science Research at Chase Capital Partners (now CCMP Capital)
- Associate Director of the Center for Biotechnology at Northwestern University
- Researcher at the National Institute of Mental Health and a start-up biotechnology company
Education
- Bachelor of Science in Molecular Biology from the University of Tennessee
- Doctorate in Molecular Biology from George Washington University in Washington, DC
- Completed graduate studies at the Kellogg Graduate School of Management at Northwestern University1
Expertise and Contributions
Dr. Johnson's expertise spans various areas of the biotechnology and pharmaceutical industries:
- Research Focus: Specialized in Alzheimer's disease and other neurodegenerative diseases
- Publications: Author of multiple peer-reviewed articles
- Patents: Holds three issued patents
- Investment Experience: Focused on high-growth opportunities in emerging areas within pharmaceutical, biotechnology, and medical device industries
- Academic Contribution: Helped develop an innovative graduate program combining science and business of biotechnology at Northwestern University1
Dr. Johnson is recognized as a leader in her field, having been featured as a panelist in discussions about women leaders in biotechnology.5 Her LinkedIn profile, under the username ginger-johnson-845437, lists her current position at Lumanity and indicates she has over 500 connections in her professional network.3
Highlights
Welcome to our first installment of our “Drill Down & Catch Up” series, part of the broader “A New Era of Neuroscience” initiative. In our initial post, we expressed cautious optimism about transformational changes in various areas of neuroscience over the next 1-5 years. Here, we highlight a few key August 2024 data readouts and regulatory decisions in psychiatric disorders and list select upcoming events in the back half of 2024, including: • A wave of new antidepressants • Psychedelics • Novel mechanisms of action for schizophrenia
To see the full installment, click here https://lnkd.in/edBjDmKt #neuroscience #psychiatric #psychedelics #depression #schizophrenia
Neuroscience is undergoing a major resurgence. After more than a decade of limited successes and cautious investment by most big pharma, a new era of innovation is unfolding. Driven by a confluence of factors – the vast unmet need (a 2021 Lancet Neurology study found 3.4 billion people worldwide suffer from nervous system disorders), and the dedication of patients, scientists, physicians, regulators, and companies have continued to de-risk the space with continued innovation on multiple fronts. We explore the latest advancements poised to reshape the future of neurosciences 2024 and beyond.
Check out the link in the comments to read the full paper written by me and my colleague, Bobby Moy at Lumanity.
#neuroscience #innovation #biotech #strategy
